Free Trial

XOMA Royalty (XOMA) Competitors

XOMA Royalty logo
$26.17 -0.79 (-2.93%)
As of 04:00 PM Eastern

XOMA vs. INVA, DVAX, MNKD, OPK, NVAX, GERN, RGLS, MYGN, ZBIO, and RIGL

Should you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry.

XOMA Royalty vs. Its Competitors

XOMA Royalty (NASDAQ:XOMA) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

XOMA Royalty presently has a consensus target price of $69.50, suggesting a potential upside of 165.57%. Innoviva has a consensus target price of $55.00, suggesting a potential upside of 190.85%. Given Innoviva's higher possible upside, analysts plainly believe Innoviva is more favorable than XOMA Royalty.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA Royalty
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Innoviva
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Innoviva has higher revenue and earnings than XOMA Royalty. XOMA Royalty is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA Royalty$28.49M11.00-$13.82M-$1.15-22.76
Innoviva$358.71M3.31$23.39M-$1.01-18.72

95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 7.2% of XOMA Royalty shares are held by insiders. Comparatively, 2.3% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, XOMA Royalty and XOMA Royalty both had 1 articles in the media. XOMA Royalty's average media sentiment score of 0.74 beat Innoviva's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
XOMA Royalty
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Innoviva
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

XOMA Royalty has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

XOMA Royalty has a net margin of -13.04% compared to Innoviva's net margin of -16.15%. Innoviva's return on equity of 15.77% beat XOMA Royalty's return on equity.

Company Net Margins Return on Equity Return on Assets
XOMA Royalty-13.04% -12.43% -4.85%
Innoviva -16.15%15.77%8.41%

Summary

Innoviva beats XOMA Royalty on 8 of the 13 factors compared between the two stocks.

Get XOMA Royalty News Delivered to You Automatically

Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XOMA vs. The Competition

MetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$322.63M$2.92B$5.53B$9.03B
Dividend YieldN/A2.44%5.24%4.01%
P/E Ratio-22.767.5519.3119.89
Price / Sales11.00284.29424.59117.07
Price / CashN/A41.7026.2128.59
Price / Book3.777.397.925.55
Net Income-$13.82M-$55.04M$3.17B$248.49M
7 Day Performance3.85%3.01%2.18%5.37%
1 Month Performance3.64%-0.21%1.25%6.63%
1 Year Performance2.11%4.48%33.90%21.20%

XOMA Royalty Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XOMA
XOMA Royalty
4.4139 of 5 stars
$26.17
-2.9%
$69.50
+165.6%
+3.1%$322.63M$28.49M-22.7610
INVA
Innoviva
3.8521 of 5 stars
$20.09
+0.7%
$55.00
+173.8%
+17.4%$1.25B$358.71M-19.89100
DVAX
Dynavax Technologies
4.3785 of 5 stars
$9.92
+0.1%
$24.00
+141.9%
-8.6%$1.19B$277.25M-19.08350
MNKD
MannKind
2.5046 of 5 stars
$3.74
-0.5%
$10.33
+176.3%
-29.7%$1.14B$285.50M37.40400Negative News
OPK
OPKO Health
4.2166 of 5 stars
$1.32
flat
$2.75
+108.3%
+6.7%$1.05B$713.10M-18.852,997
NVAX
Novavax
4.4626 of 5 stars
$6.30
-1.1%
$17.00
+169.8%
-42.9%$1.03B$682.16M2.381,990
GERN
Geron
2.8378 of 5 stars
$1.41
-5.4%
$5.06
+259.0%
-68.5%$949.01M$76.99M-6.7170
RGLS
Regulus Therapeutics
1.5746 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
MYGN
Myriad Genetics
4.1191 of 5 stars
$5.31
+1.1%
$14.38
+170.9%
-77.5%$483.93M$837.60M-4.742,700
ZBIO
Zenas BioPharma
1.1838 of 5 stars
$9.69
+1.1%
$36.67
+278.4%
N/A$400.77M$5M-2.73N/APositive News
RIGL
Rigel Pharmaceuticals
2.3807 of 5 stars
$18.73
-3.9%
$36.40
+94.3%
+143.1%$348.15M$179.28M9.05160

Related Companies and Tools


This page (NASDAQ:XOMA) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners